Published in World J Transplant on March 24, 2014
Safety & Tolerability of Berinert® (C1 Inhibitor) Therapy to Prevent Rejection | NCT01134510
Desensitization With Belimumab in Sensitized Patients Awaiting Kidney Transplant | NCT01025193
Transient blockade of delta-like Notch ligands prevents allograft rejection mediated by cellular and humoral mechanisms in a mouse model of heart transplantation. J Immunol (2015) 0.80
Challenges in pediatric renal transplantation. World J Transplant (2014) 0.77
Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial. Lancet (2011) 8.89
Banff 07 classification of renal allograft pathology: updates and future directions. Am J Transplant (2008) 8.09
Desensitization in HLA-incompatible kidney recipients and survival. N Engl J Med (2011) 6.72
KDIGO clinical practice guideline for the care of kidney transplant recipients. Am J Transplant (2009) 6.43
Banff '05 Meeting Report: differential diagnosis of chronic allograft injury and elimination of chronic allograft nephropathy ('CAN'). Am J Transplant (2007) 5.39
Anti-inflammatory activity of IVIG mediated through the inhibitory Fc receptor. Science (2001) 4.62
Rituximab and intravenous immune globulin for desensitization during renal transplantation. N Engl J Med (2008) 4.32
Understanding the causes of kidney transplant failure: the dominant role of antibody-mediated rejection and nonadherence. Am J Transplant (2011) 4.06
Antibody-mediated microcirculation injury is the major cause of late kidney transplant failure. Am J Transplant (2009) 3.43
Capillary deposition of complement split product C4d in renal allografts is associated with basement membrane injury in peritubular and glomerular capillaries: a contribution of humoral immunity to chronic allograft rejection. J Am Soc Nephrol (2002) 3.34
Banff '09 meeting report: antibody mediated graft deterioration and implementation of Banff working groups. Am J Transplant (2010) 3.29
Antibody-mediated renal allograft rejection: diagnosis and pathogenesis. J Am Soc Nephrol (2007) 2.64
Evidence for antibody-mediated injury as a major determinant of late kidney allograft failure. Transplantation (2010) 2.59
Consensus guidelines on the testing and clinical management issues associated with HLA and non-HLA antibodies in transplantation. Transplantation (2013) 2.55
Evolution and clinical pathologic correlations of de novo donor-specific HLA antibody post kidney transplant. Am J Transplant (2012) 2.46
Kidney allograft survival after acute rejection, the value of follow-up biopsies. Am J Transplant (2013) 2.35
Banff 2011 Meeting report: new concepts in antibody-mediated rejection. Am J Transplant (2012) 2.28
Endothelial gene expression in kidney transplants with alloantibody indicates antibody-mediated damage despite lack of C4d staining. Am J Transplant (2009) 2.27
De novo donor-specific antibody at the time of kidney transplant biopsy associates with microvascular pathology and late graft failure. Am J Transplant (2009) 2.24
Mechanisms of rejection: current perspectives. Transplantation (2012) 2.19
A novel pathway of chronic allograft rejection mediated by NK cells and alloantibody. Am J Transplant (2011) 2.16
Daclizumab versus antithymocyte globulin in high-immunological-risk renal transplant recipients. J Am Soc Nephrol (2009) 2.08
Biologics in organ transplantation. Transpl Int (2012) 2.06
National conference to assess antibody-mediated rejection in solid organ transplantation. Am J Transplant (2004) 2.01
Antibody-mediated organ-allograft rejection. Nat Rev Immunol (2005) 1.99
Terminal complement inhibition decreases antibody-mediated rejection in sensitized renal transplant recipients. Am J Transplant (2011) 1.98
Three-year outcomes from BENEFIT, a randomized, active-controlled, parallel-group study in adult kidney transplant recipients. Am J Transplant (2011) 1.93
Summary of FDA antibody-mediated rejection workshop. Am J Transplant (2011) 1.87
Plasmapheresis and intravenous immune globulin provides effective rescue therapy for refractory humoral rejection and allows kidneys to be successfully transplanted into cross-match-positive recipients. Transplantation (2000) 1.85
Use of intravenous immune globulin and rituximab for desensitization of highly HLA-sensitized patients awaiting kidney transplantation. Transplantation (2010) 1.83
Pretransplant donor-specific antibodies in cytotoxic negative crossmatch kidney transplants: are they relevant? Transplantation (2008) 1.82
Predicting subsequent decline in kidney allograft function from early surveillance biopsies. Am J Transplant (2005) 1.79
Rituximab, an anti-cd20 monoclonal antibody: history and mechanism of action. Am J Transplant (2006) 1.78
Chronic humoral rejection: identification of antibody-mediated chronic renal allograft rejection by C4d deposits in peritubular capillaries. J Am Soc Nephrol (2001) 1.72
The impact of donor-specific anti-HLA antibodies on late kidney allograft failure. Nat Rev Nephrol (2012) 1.71
Bortezomib provides effective therapy for antibody- and cell-mediated acute rejection. Transplantation (2008) 1.66
Significance of C4d Banff scores in early protocol biopsies of kidney transplant recipients with preformed donor-specific antibodies (DSA). Am J Transplant (2011) 1.66
BAFF and BAFF-R levels are associated with risk of long-term kidney graft dysfunction and development of donor-specific antibodies. Am J Transplant (2012) 1.60
Four-year follow-up of a prospective trial of HLA and MICA antibodies on kidney graft survival. Am J Transplant (2007) 1.60
Cryptic B cell response to renal transplantation. Am J Transplant (2013) 1.57
Antiperlecan antibodies are novel accelerators of immune-mediated vascular injury. Am J Transplant (2013) 1.56
Comparison of combination Plasmapheresis/IVIg/anti-CD20 versus high-dose IVIg in the treatment of antibody-mediated rejection. Am J Transplant (2009) 1.52
In vitro detection of C4d-fixing HLA alloantibodies: associations with capillary C4d deposition in kidney allografts. Am J Transplant (2007) 1.52
Neither pre-transplant rituximab nor splenectomy affects de novo HLA antibody production after renal transplantation. Kidney Int (2013) 1.51
Clinical relevance of preformed HLA donor-specific antibodies in kidney transplantation. Am J Transplant (2007) 1.49
IVIG and HLA antibodies. Evidence for inhibition of complement activation but not for anti-idiotypic activity. Am J Transplant (2005) 1.46
De novo development of circulating anti-endothelial cell antibodies rather than pre-existing antibodies is associated with post-transplant allograft rejection. Kidney Int (2010) 1.45
Novel C1q assay reveals a clinically relevant subset of human leukocyte antigen antibodies independent of immunoglobulin G strength on single antigen beads. Hum Immunol (2011) 1.40
Transplanting patients with a positive donor-specific crossmatch: a single center's perspective. Pediatr Transplant (2004) 1.38
Frequency and clinical implications of development of donor-specific and non-donor-specific HLA antibodies after kidney transplantation. J Am Soc Nephrol (2005) 1.36
The use of antibody to complement protein C5 for salvage treatment of severe antibody-mediated rejection. Am J Transplant (2008) 1.34
Incidence and impact of de novo donor-specific alloantibody in primary renal allografts. Transplantation (2013) 1.33
C4d fixing, luminex binding antibodies - a new tool for prediction of graft failure after heart transplantation. Am J Transplant (2007) 1.24
Impact of rituximab therapy for treatment of acute humoral rejection. Clin Transplant (2009) 1.22
Desensitization protocols and their outcome. Clin J Am Soc Nephrol (2011) 1.21
The importance of anti-HLA-specific antibody strength in monitoring kidney transplant patients. Am J Transplant (2007) 1.19
Anti-angiotensin type 1 receptor antibodies associated with antibody mediated rejection in donor HLA antibody negative patients. Transplantation (2010) 1.15
Pathological and clinical characterization of the 'troubled transplant': data from the DeKAF study. Am J Transplant (2010) 1.14
Revisiting traditional risk factors for rejection and graft loss after kidney transplantation. Am J Transplant (2011) 1.14
Pretransplant donor-specific HLA class-I and -II antibodies are associated with an increased risk for kidney graft failure. Am J Transplant (2012) 1.13
Autoantibodies to vimentin cause accelerated rejection of cardiac allografts. Am J Pathol (2007) 1.12
Four stages and lack of stable accommodation in chronic alloantibody-mediated renal allograft rejection in Cynomolgus monkeys. Am J Transplant (2008) 1.11
Histopathologic clusters differentiate subgroups within the nonspecific diagnoses of CAN or CR: preliminary data from the DeKAF study. Am J Transplant (2009) 1.10
Formalization of the MESF unit of fluorescence intensity. Cytometry B Clin Cytom (2004) 1.10
Intravenous immune globulin treatment inhibits crossmatch positivity and allows for successful transplantation of incompatible organs in living-donor and cadaver recipients. Transplantation (2003) 1.08
Relevance of different antibody detection methods for the prediction of antibody-mediated rejection and deceased-donor kidney allograft survival. Hum Immunol (2009) 1.08
Donor-specific antibodies accelerate arteriosclerosis after kidney transplantation. J Am Soc Nephrol (2011) 1.07
Posttransplant de novo donor-specific hla antibodies identify pediatric kidney recipients at risk for late antibody-mediated rejection. Am J Transplant (2012) 1.07
The utility of splenectomy as rescue treatment for severe acute antibody mediated rejection. Am J Transplant (2007) 1.05
Multicenter evaluation of a novel endothelial cell crossmatch test in kidney transplantation. Transplantation (2009) 1.05
Non-HLA antibodies to immunogenic epitopes predict the evolution of chronic renal allograft injury. J Am Soc Nephrol (2012) 1.05
Transfer of tolerance to collagen type V suppresses T-helper-cell-17 lymphocyte-mediated acute lung transplant rejection. Transplantation (2009) 1.04
The treatment of acute antibody-mediated rejection in kidney transplant recipients-a systematic review. Transplantation (2012) 1.03
The role of proteasome inhibition with bortezomib in the treatment of antibody-mediated rejection after kidney-only or kidney-combined organ transplantation. Transplantation (2010) 1.03
Combined posttransplant prophylactic IVIg/anti-CD 20/plasmapheresis in kidney recipients with preformed donor-specific antibodies: a pilot study. Transplantation (2010) 1.03
Nondepleting anti-CD40-based therapy prolongs allograft survival in nonhuman primates. Am J Transplant (2011) 0.99
Successful treatment of chronic antibody-mediated rejection with IVIG and rituximab in pediatric renal transplant recipients. Transplantation (2008) 0.97
Tools for human leukocyte antigen antibody detection and their application to transplanting sensitized patients. Transplantation (2008) 0.97
Donor-specific antibody levels and three generations of crossmatches to predict antibody-mediated rejection in kidney transplantation. Transplantation (2010) 0.95
Comparison between bortezomib and rituximab in the treatment of antibody-mediated renal allograft rejection. Nephrol Dial Transplant (2011) 0.95
Humoral responses directed against non-human leukocyte antigens in solid-organ transplantation. Transplantation (2008) 0.95
Rituximab and intravenous immunoglobulin treatment of chronic antibody-mediated kidney allograft rejection. Transplantation (2009) 0.94
Microcirculation inflammation associates with outcome in renal transplant patients with de novo donor-specific antibodies. Am J Transplant (2012) 0.94
ASKP1240, a fully human anti-CD40 monoclonal antibody, prolongs pancreatic islet allograft survival in nonhuman primates. Am J Transplant (2013) 0.94
Successful rescue of refractory, severe antibody mediated rejection with splenectomy. Transplantation (2007) 0.92
Regulation of immunity and inflammation by intravenous immunoglobulin: relevance to solid organ transplantation. Expert Rev Clin Immunol (2011) 0.92
Clinical relevance of pretransplant anti-HLA donor-specific antibodies: does C1q-fixation matter? Transpl Immunol (2013) 0.92
Molecular diversity of cardiac endothelial cells in vitro and in vivo. Physiol Genomics (2004) 0.91
Antibodies reactive to non-HLA antigens in transplant glomerulopathy. J Am Soc Nephrol (2011) 0.91
Non-MHC antigenic targets of the humoral immune response in transplantation. Curr Opin Immunol (2010) 0.91
Advances in diagnosing and managing antibody-mediated rejection. Pediatr Nephrol (2010) 0.90
A phase 1, randomized ascending single-dose study of antagonist anti-human CD40 ASKP1240 in healthy subjects. Am J Transplant (2013) 0.90
Elevated pretransplantation soluble BAFF is associated with an increased risk of acute antibody-mediated rejection. Transplantation (2013) 0.89
Anti-donor HLA class I antibodies: pathways to endothelial cell activation and cell-mediated allograft rejection. Transplantation (2013) 0.89
Early versus late acute antibody-mediated rejection in renal transplant recipients. Transplantation (2013) 0.89
Endothelial injury in renal antibody-mediated allograft rejection: a schematic view based on pathogenesis. Transplantation (2013) 0.88
Prompt reversal of a severe complement activation by eculizumab in a patient undergoing intentional ABO-incompatible pancreas and kidney transplantation. Transpl Int (2011) 0.88
The impact of c4d pattern and donor-specific antibody on graft survival in recipients requiring indication renal allograft biopsy. Am J Transplant (2009) 0.88
Advances in the understanding of transplant glomerulopathy. Am J Kidney Dis (2013) 0.88
Chronic alloantibody mediated rejection. Semin Immunol (2011) 0.87
Update on ischemia-reperfusion injury in kidney transplantation: Pathogenesis and treatment. World J Transplant (2015) 0.90
Is it time to give up with calcineurin inhibitors in kidney transplantation? World J Transplant (2013) 0.86
Complement involvement in kidney diseases: From physiopathology to therapeutical targeting. World J Nephrol (2015) 0.80
Complement related kidney diseases: Recurrence after transplantation. World J Transplant (2016) 0.75